Small molecule · Inhibitor of poly(ADP-ribose) polymerase 1 (PARP1) · developed by BeiGene
Pamiparib is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase (PARP). It binds PARP and blocks PARP-mediated repair of single-strand DNA breaks through the base-excision repair pathway, leading to accumulation of DNA strand breaks and apoptosis. It is being studied in solid tumors and ovarian cancers, including platinum-resistant ovarian cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05494580 | Phase 1/2 | Ovarian Cancer | Completed | HCM |
| NCT03150810 | Phase 1 | Locally Advanced or Metastatic Solid Tumors | Completed | MYGN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Fallopian Tube CarcinosarcomaLocally Advanced or Metastatic Solid TumorsOvarian CancerOvarian CarcinomaPlatinum-resistant Ovarian CancerPrimary Peritoneal Cancer